Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.30
Dollar change
+0.02
Percentage change
1.56
%
Index- P/E- EPS (ttm)-2.11 Insider Own7.53% Shs Outstand89.93M Perf Week-5.80%
Market Cap116.91M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float83.16M Perf Month-6.47%
Income-93.61M PEG- EPS next Q-0.26 Inst Own21.04% Short Float2.98% Perf Quarter-14.47%
Sales0.00M P/S- EPS this Y52.61% Inst Trans-2.58% Short Ratio2.45 Perf Half Y-3.70%
Book/sh0.64 P/B2.03 EPS next Y0.67% ROA-102.84% Short Interest2.47M Perf Year-15.03%
Cash/sh0.52 P/C2.51 EPS next 5Y15.50% ROE-131.28% 52W Range0.95 - 3.11 Perf YTD-13.33%
Dividend Est.- P/FCF- EPS past 5Y31.12% ROI-316.58% 52W High-58.20% Beta2.08
Dividend TTM- Quick Ratio2.12 Sales past 5Y0.00% Gross Margin- 52W Low37.55% ATR (14)0.09
Dividend Ex-Date- Current Ratio2.12 EPS Y/Y TTM44.20% Oper. Margin0.00% RSI (14)46.09 Volatility4.32% 6.86%
Employees77 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price11.88
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q70.32% Payout- Rel Volume0.17 Prev Close1.28
Sales Surprise- EPS Surprise6.34% Sales Q/Q- EarningsFeb 22 BMO Avg Volume1.01M Price1.30
SMA20-6.42% SMA500.88% SMA200-13.65% Trades Volume170,627 Change1.56%
Date Action Analyst Rating Change Price Target Change
Oct-21-22Downgrade SVB Leerink Outperform → Mkt Perform $5
Sep-19-22Resumed H.C. Wainwright Buy $26
Apr-15-21Initiated Aegis Capital Buy $55
Mar-24-21Initiated JMP Securities Mkt Outperform $55
Oct-02-20Initiated SVB Leerink Outperform $45
Aug-26-20Initiated Piper Sandler Overweight $71
Aug-07-20Resumed ROTH Capital Buy $64
Jul-20-20Initiated BMO Capital Markets Outperform $40
Jun-05-20Initiated Wedbush Outperform $59
May-11-20Initiated H.C. Wainwright Buy $45
Mar-21-24 12:14PM
11:37AM
Mar-20-24 06:30AM
Mar-08-24 06:53AM
Mar-07-24 06:30AM
06:30AM Loading…
Feb-29-24 06:30AM
Feb-23-24 09:02PM
11:04AM
Feb-22-24 10:59AM
06:30AM
Feb-15-24 06:30AM
Feb-01-24 06:30AM
Jan-05-24 06:35AM
06:30AM
Nov-21-23 06:30AM
01:25PM Loading…
Nov-14-23 01:25PM
06:36AM
06:30AM
Nov-07-23 06:30AM
Nov-02-23 06:30AM
Oct-26-23 06:30AM
Oct-24-23 07:51AM
Oct-16-23 06:30AM
Oct-15-23 06:30AM
Oct-11-23 06:30AM
05:15AM
Oct-10-23 09:07AM
Oct-09-23 04:01PM
Oct-04-23 06:30AM
Sep-06-23 06:30AM
08:00AM Loading…
Aug-21-23 08:00AM
Aug-17-23 06:30AM
Aug-07-23 09:50AM
Aug-03-23 06:47AM
06:30AM
Aug-01-23 06:30AM
Jul-28-23 04:19PM
Jul-27-23 06:30AM
Jul-25-23 08:00AM
Jul-24-23 10:33AM
Jun-29-23 06:30AM
Jun-27-23 09:56AM
09:11AM
Jun-26-23 03:44PM
May-31-23 07:42AM
May-30-23 06:30AM
May-17-23 10:00AM
06:30AM
May-16-23 01:07PM
May-11-23 06:40AM
06:30AM
May-09-23 06:30AM
May-06-23 06:30AM
May-04-23 06:30AM
Apr-27-23 06:30AM
Apr-26-23 06:30AM
Apr-13-23 08:00AM
Apr-06-23 02:10PM
Apr-05-23 12:30PM
06:30AM
Mar-02-23 06:30AM
Feb-28-23 05:22AM
Feb-26-23 08:23AM
Feb-23-23 06:30AM
Feb-22-23 06:30AM
Feb-16-23 06:30AM
Feb-09-23 06:30AM
Jan-25-23 06:30AM
Jan-18-23 06:31AM
Nov-17-22 08:04AM
06:30AM
Nov-10-22 06:30AM
Nov-03-22 06:30AM
Oct-27-22 06:30AM
Oct-21-22 03:14PM
06:52AM
Oct-20-22 04:01PM
Oct-10-22 07:00AM
Oct-04-22 06:30AM
Sep-20-22 01:39PM
06:30AM
Sep-19-22 03:03PM
Sep-16-22 10:11AM
Sep-01-22 06:30AM
Aug-16-22 06:30AM
Aug-04-22 06:30AM
Aug-02-22 06:30AM
Jul-28-22 06:30AM
Jul-18-22 09:04AM
Jul-07-22 12:00PM
Jul-06-22 06:30AM
Jun-28-22 06:30AM
Jun-15-22 06:30AM
Jun-08-22 06:30AM
Jun-03-22 10:51AM
Jun-02-22 06:30AM
May-15-22 08:38AM
May-10-22 06:30AM
May-05-22 06:30AM
May-03-22 06:30AM
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whaley GlennChief Financial OfficerMay 15 '23Buy1.755,0008,75025,510May 16 08:30 AM